drugset / Trial / NCT02483858
Study of Oral PQR309 in Patients With Advanced Solid Tumors
Phase 1
Completed
70 enrolled
PIQUR Therapeutics AG
Case Western Reserve University · collabChurchill Hospital · collabHospital Clinic of Barcelona · collabM.D. Anderson Cancer Center · collabMayo Clinic · collabRoswell Park Cancer Institute · collabUniversity College London Hospitals · collabUniversity Hospital, Zürich · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.
Timeline
- Start
- 2019-03-21
- Primary completion
- 2019-03-21
- Completion
- 2019-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimiralisib | Small molecule | 80 mg | Oral |
| Subject | Bimiralisib | Small molecule | 100 mg | Oral |
| Subject | Bimiralisib | Small molecule | 120 mg | Oral |